why does nobody talk about tendon
The title is the whole question — why does nobody talk about tendon — but here is why I am asking.
Kept a reconstituted vial too long out of curiosity and learned something about solution stability I would rather have read.
Assumed regulatory status was static and it was not. Checked again this year and the answer had changed where I live.
Asked WWB for the theoretical mass alongside the certificate and they sent it without asking why.
I will update this if the picture changes rather than quietly leaving it up.
best — the order this archive was captured in
The published literature is overwhelmingly preclinical, largely in rodent models. Translating a rodent result into a human expectation is not a small step, and almost every confident claim here takes it silently.
Ask for the theoretical mass alongside the measured one. It is a one-line addition to a certificate and it converts a purity claim into an identity claim.
Regulatory classification differs between jurisdictions and has changed in several of them recently. Any answer to a status question needs a place and a date attached.
pentadecapeptide, fifteen residues, and the sequence is public
Cosigning that the papers are more modest than the summaries of them. That is true across this whole site and especially here.
Was there identity confirmation, or only a purity figure?
identity testing matters more here than purity does
The published literature is overwhelmingly preclinical, largely in rodent models.
Adding the standing caveat — research material is not approved for human use, wherever you are.
Correction: that study was in rodents. Worth stating explicitly since the thread has been reading it as clinical.
Reconstituted or powder, and how long has it been in solution?
I would not extrapolate a mechanism from a model system to a person in one step, which is what that comment does.
short peptides are cheap, which cuts both ways
That claim traces back to a single preclinical paper that says something considerably narrower.
preclinical enthusiasm is not clinical evidence
Small fix — fifteen residues, not seventeen. The sequence is public and easy to check.
the tendon claims are the most repeated and the least evidenced
Standing reminder in every thread here: research material is not approved for human use.
Bought small, tested identity first, and only then thought about anything else. That order felt right.
research-use-only means not approved for human use, and here that covers everything
This. Mass spectrometry for identity, not just an area percent, because a pure something-else is still something else.
It is a fifteen-residue peptide with a published sequence, which makes synthesis straightforward and makes identity verification the meaningful test rather than an optional extra.
Short peptides in solution are subject to hydrolysis and, depending on sequence, oxidation. Storage state and time in solution are practical variables that this board almost never discusses.
It is a fifteen-residue peptide with a published sequence, which makes synthesis straightforward and makes identity verification the meaningful test r
Disagreeing with this line: that paper is in a rodent model and it is being quoted as a human result.
Disagreeing with this line: that paper is in a rodent model and it is being quoted as a human result.
Agreed — and the preclinical to clinical gap is where nearly all the overclaiming happens.
a fifteen-residue peptide is easy to make and easy to make badly
What jurisdiction are you asking about? The answer has changed in several.
- 1The published literature is overwhelmingly preclinical, largely in rodent…17 comments in this branch · started by u/enzo_ferrari
- 2It is a fifteen-residue peptide with a published sequence, which makes…6 comments in this branch · started by u/elodie_yilmaz